Public Act 100-0218 Public Act 0218 100TH GENERAL ASSEMBLY |
Public Act 100-0218 | SB0636 Enrolled | LRB100 06838 SMS 16887 b |
|
| AN ACT concerning regulation.
| Be it enacted by the People of the State of Illinois,
| represented in the General Assembly:
| Section 5. The Pharmacy Practice Act is amended by changing | Section 4 as follows:
| (225 ILCS 85/4) (from Ch. 111, par. 4124)
| (Section scheduled to be repealed on January 1, 2018)
| Sec. 4. Exemptions. Nothing contained in any Section of | this Act shall
apply
to, or in any manner interfere with:
| (a) the lawful practice of any physician licensed to | practice medicine in
all of its branches, dentist, podiatric | physician,
veterinarian, or therapeutically or diagnostically | certified optometrist within
the limits of
his or her license, | or prevent him or her from
supplying to his
or her
bona fide | patients
such drugs, medicines, or poisons as may seem to him | appropriate;
| (b) the sale of compressed gases;
| (c) the sale of patent or proprietary medicines and | household remedies
when sold in original and unbroken packages | only, if such patent or
proprietary medicines and household | remedies be properly and adequately
labeled as to content and | usage and generally considered and accepted
as harmless and | nonpoisonous when used according to the directions
on the |
| label, and also do not contain opium or coca leaves, or any
| compound, salt or derivative thereof, or any drug which, | according
to the latest editions of the following authoritative | pharmaceutical
treatises and standards, namely, The United | States Pharmacopoeia/National
Formulary (USP/NF), the United | States Dispensatory, and the Accepted
Dental Remedies of the | Council of Dental Therapeutics of the American
Dental | Association or any or either of them, in use on the effective
| date of this Act, or according to the existing provisions of | the Federal
Food, Drug, and Cosmetic Act and Regulations of the | Department of Health
and Human Services, Food and Drug | Administration, promulgated thereunder
now in effect, is | designated, described or considered as a narcotic,
hypnotic, | habit forming, dangerous, or poisonous drug;
| (d) the sale of poultry and livestock remedies in original | and unbroken
packages only, labeled for poultry and livestock | medication;
| (e) the sale of poisonous substances or mixture of | poisonous substances,
in unbroken packages, for nonmedicinal | use in the arts or industries
or for insecticide purposes; | provided, they are properly and adequately
labeled as to | content and such nonmedicinal usage, in conformity
with the | provisions of all applicable federal, state and local laws
and | regulations promulgated thereunder now in effect relating | thereto
and governing the same, and those which are required | under such applicable
laws and regulations to be labeled with |
| the word "Poison", are also labeled
with the word "Poison" | printed
thereon in prominent type and the name of a readily | obtainable antidote
with directions for its administration;
| (f) the delegation of limited prescriptive authority by a | physician
licensed to
practice medicine in all its branches to | a physician assistant
under Section 7.5 of the Physician | Assistant Practice Act of 1987. This
delegated authority under | Section 7.5 of the Physician Assistant Practice Act of 1987 | may, but is not required to, include prescription of
controlled | substances, as defined in Article II of the
Illinois Controlled | Substances Act, in accordance with a written supervision | agreement; and
| (g) the delegation of prescriptive authority by a physician
| licensed to practice medicine in all its branches or a licensed | podiatric physician to an advanced practice
nurse in accordance | with a written collaborative
agreement under Sections 65-35 and | 65-40 of the Nurse Practice Act ; and .
| (h) the sale or distribution of dialysate or devices | necessary to perform home peritoneal renal dialysis for | patients with end-stage renal disease, provided that all of the | following conditions are met: | (1) the dialysate, comprised of dextrose or | icodextrin, or devices are approved or cleared by the | federal Food and Drug Administration, as required by | federal law; | (2) the dialysate or devices are lawfully held by a |
| manufacturer or the manufacturer's agent, which is | properly registered with the Board as a manufacturer or | wholesaler; | (3) the dialysate or devices are held and delivered to | the manufacturer or the manufacturer's agent in the | original, sealed packaging from the manufacturing | facility; | (4) the dialysate or devices are delivered only upon | receipt of a physician's prescription by a licensed | pharmacy in which the prescription is processed in | accordance with provisions set forth in this Act, and the | transmittal of an order from the licensed pharmacy to the | manufacturer or the manufacturer's agent; and | (5) the manufacturer or the manufacturer's agent | delivers the dialysate or devices directly to: (i) a | patient with end-stage renal disease, or his or her | designee, for the patient's self-administration of the | dialysis therapy or (ii) a health care provider or | institution for administration or delivery of the dialysis | therapy to a patient with end-stage renal disease. | This paragraph (h) does not include any other drugs for | peritoneal dialysis, except dialysate, as described in item (1) | of this paragraph (h). All records of sales and distribution of | dialysate to patients made pursuant to this paragraph (h) must | be retained in accordance with Section 18 of this Act. | (Source: P.A. 98-214, eff. 8-9-13.)
|
| Section 99. Effective date. This Act takes effect upon | becoming law.
|
Effective Date: 8/18/2017
|